• By Fierce Biotech   -   May 18, 2021

    BRISTOL MYERS HANDS OVER $200M UPFRONT, $1.36B IN BIOBUCKS FOR AGENUS' PRECLINICAL TIGIT ASSET

    Bristol Myers hands over $200M upfront, $1.36B in biobucks for Agenus' preclinical TIGIT asset badams Tue, 05/18/2021 - 08:06

  • By Fierce Biotech   -   May 18, 2021

    MEDICAGO, GSK POST POSITIVE MIDPHASE DATA ON PLANT-DERIVED COVID-19 VACCINE

    Medicago, GSK post positive midphase data on plant-derived COVID-19 vaccine ntaylor Tue, 05/18/2021 - 05:23

    Vaccines, Vaccine, Plants
  • By Fierce Biotech   -   May 18, 2021

    EUREKARE RAISES $60M TO CREATE EU SYNBIO AND MICROBIOME STARTUPS

    EureKARE raises $60M to create EU synbio and microbiome startups ntaylor Mon, 05/17/2021 - 10:06

  • By Fierce Biotech   -   May 18, 2021

    NEW INSIGHT INTO AGGRESSIVE BREAST CANCER COULD DRIVE TREATMENT CHOICES

    New insight into aggressive breast cancer could drive treatment choices arlene.weintraub Mon, 05/17/2021 - 13:22

    Cancer
  • By Fierce Biotech   -   May 18, 2021

    LANDOS BIOPHARMA TEAMS UP WITH LIANBIO FOR $218M-PLUS COLLAB AND SALES DEAL FOR 2 IMMUNOLOGY ASSETS IN ASIA

    Landos Biopharma teams up with LianBio for $218M-plus collab and sales deal for 2 immunology assets in Asia badams Fri, 05/14/2021...

    Asia, BioPharma, Biopharma, Immunology
  • By Fierce Biotech   -   May 18, 2021

    ACC 2021: WITH AMGEN OUT OF THE PICTURE, CYTOKINETICS IMAGINES SUPPORTING ROLE FOR OMECAMTIV IN HEART FAILURE

    ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure aarmstrong Sun, 05/16/2021...

  • By Fierce Biotech   -   May 18, 2021

    PRECISIONLIFE, CYCLICA ALLY TO CO-MARKET COMPUTATIONAL DISCOVERY PLATFORMS

    PrecisionLife, Cyclica ally to co-market computational discovery platforms ntaylor Mon, 05/17/2021 - 07:47

    Discovery, Computers
  • By Fierce Biotech   -   May 18, 2021

    INCYTE'S RUXOLITINIB CREAM HITS GOAL IN VITILIGO PHASE 3 TRIALS, TEEING UP REGULATORY SUBMISSIONS

    Incyte's ruxolitinib cream hits goal in vitiligo phase 3 trials, teeing up regulatory submissions ntaylor Mon, 05/17/2021 - 08:45

  • By Fierce Biotech   -   May 18, 2021

    PREPPING THE NEXT GENERATION OF COVID-19 VACCINES AND TREATMENTS

    Prepping the next generation of COVID-19 vaccines and treatments arlene.weintraub Mon, 05/17/2021 - 08:55

    Vaccines, Vaccine
  • By Fierce Biotech   -   May 18, 2021

    2ND TIME LUCKY FOR SANOFI-GSK AFTER PASSING SMALL MIDSTAGE COVID SHOT; EYE APPROVAL BY YEAR-END

    2nd time lucky for Sanofi-GSK after passing small midstage COVID shot; eye approval by year-end badams Sun, 05/16/2021 - 12:38

  • By Fierce Biotech   -   May 18, 2021

    CHUTES & LADDERS-GOSSAMER VET SALTER-CID DONS CSO MANTLE AT FLAGSHIP'S NEW PIONEERING MEDICINES UNIT

    Chutes & Ladders-Gossamer vet Salter-Cid dons CSO mantle at Flagship's new Pioneering Medicines unit fkansteiner Thu, 05/13/2021 -...

    Medicine
  • By Fierce Biotech   -   May 18, 2021

    KINNATE, ORBIMED TEAM UP TO TARGET CHINESE LUNG CANCER MARKET

    Kinnate, OrbiMed team up to target Chinese lung cancer market ntaylor Fri, 05/14/2021 - 06:44

    Cancer
  • By Fierce Biotech   -   May 18, 2021

    COMPASS INKS TRIGR TAKEOVER TO LAND CLINICAL-PHASE BISPECIFIC

    Compass inks Trigr takeover to land clinical-phase bispecific ntaylor Fri, 05/14/2021 - 07:51

    Clinical
  • By Fierce Biotech   -   May 18, 2021

    OTONOMY EYES CLINICAL TRIAL OF HEARING LOSS GENE THERAPY WITH PROMISING ANIMAL DATA

    Otonomy eyes clinical trial of hearing loss gene therapy with promising animal data aliu Fri, 05/14/2021 - 08:56

    Therapies, Gene Therapy, Genes, Gene, Animals, Clinical
  • By Fierce Biotech   -   May 18, 2021

    WITH A NEW CMO AND PHASE 3 DATA TO HAND, HUMANIGEN EYES COVID-19 DRUG EMERGENCY FILING BY JUNE

    With a new CMO and phase 3 data to hand, Humanigen eyes COVID-19 drug emergency filing by June badams Fri, 05/14/2021 - 04:22

    Drugs, Drug
  • By Fierce Biotech   -   May 18, 2021

    HOW A GENETIC 'COPYCATCHER' COULD OPEN THE DOOR TO CRISPR-BASED PRECISION GENE THERAPY

    How a genetic 'CopyCatcher' could open the door to CRISPR-based precision gene therapy aliu Thu, 05/13/2021 - 07:26

    Therapies, Gene, Genes, Gene Therapy, Genetics
  • By Fierce Biotech   -   May 18, 2021

    AUTOLUS' CD19 CAR-T POSTS 100% COMPLETE RESPONSE RATE, ZERO GRADE 3 CRS IN SMALL LYMPHOMA TRIAL

    Autolus' CD19 CAR-T posts 100% complete response rate, zero grade 3 CRS in small lymphoma trial ntaylor Thu, 05/13/2021 - 07:33

  • By Fierce Biotech   -   May 18, 2021

    NEA-BACKED ALLAY EXITS STEALTH WITH CLINICAL PAIN DATA, PLANS TO REDUCE NEED FOR OPIOIDS

    NEA-backed Allay exits stealth with clinical pain data, plans to reduce need for opioids ntaylor Thu, 05/13/2021 - 08:09

    Clinical
  • By Fierce Biotech   -   May 18, 2021

    AMGEN, ASTRAZENECA'S TEZEPELUMAB IS LOOKING FOR A SLICE OF BLOCKBUSTER ASTHMA MARKET DOMINATED BY SANOFI'S DUPIXENT

    Amgen, AstraZeneca's tezepelumab is looking for a slice of blockbuster asthma market dominated by Sanofi's Dupixent aarmstrong Tue,...

  • By Fierce Biotech   -   May 18, 2021

    CALL FOR YOUR FIERCE BIOTECH FIERCE 15 NOMINATIONS FOR 2021

    Call for your Fierce Biotech Fierce 15 nominations for 2021 badams Wed, 05/12/2021 - 05:05

    Biotech, BioTech